Liprimar film-coated tablets 40 mg blister No. 30

Liprimar film-coated tablets are indicated for:

Composition

Active ingredient: atorvastatin;

1 tablet contains atorvastatin calcium equivalent to 10 mg or 20 mg, 40 mg, or 80 mg of atorvastatin;

Excipients: calcium carbonate; microcrystalline cellulose, lactose monohydrate, croscarmellose sodium; polysorbate 80, hydroxypropylcellulose; magnesium stearate, film-coating material (hydroxypropylmethylcellulose, polyethylene glycol 8000, titanium dioxide (E 171), talc), simethicone emulsion (simethicone, emulsifier stearate, thickener, benzoic acid, sorbic acid).

Contraindication

Method of application

Before starting atorvastatin therapy, the level of hypercholesterolemia should be determined against the background of an appropriate diet, physical exercises and measures aimed at reducing body weight in obese patients should be prescribed, and other diseases should be treated. During treatment with atorvastatin, patients should adhere to a standard low-cholesterol diet. The drug should be administered at a dose of 10-80 mg 1 time per day daily, at any time of the day, regardless of meals. The starting and maintenance dose can be individualized according to the initial level of LDL-C, the goals of therapy and its effectiveness. 2-4 weeks after the start of treatment and / or dose adjustment of atorvastatin, the lipid profile should be determined and the dose adjusted accordingly.

Application features

Pregnant women

Contraindicated.

Children

From the age of 10.

Drivers

It has a very slight effect on the reaction speed when driving or working with other mechanisms.

Overdose

There is no specific treatment for atorvastatin overdose. In case of overdose, the patient should be treated symptomatically and, if necessary, supportive measures should be applied. Given the high degree of binding of the drug to plasma proteins, a significant increase in the clearance of atorvastatin by hemodialysis should not be expected.

Side effects

Atorvastatin is generally well tolerated.

Adverse reactions include: chest pain, facial edema, fever, asthenia, neck stiffness, weakness, photosensitivity reactions, generalized edema, malaise, pyrexia, peripheral edema.

Interaction

The risk of myopathy during statin treatment is increased with concomitant use of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or potent CYP 3A4 inhibitors (e.g. clarithromycin, HIV protease inhibitors, and itraconazole).

Grapefruit juice. Contains one or more components that inhibit CYP 3A4 and may increase plasma concentrations of atorvastatin, especially with excessive consumption of grapefruit juice (more than 1.2 liters per day).

Atorvastatin and its metabolites are substrates of the OATP1B1 transporter. OATP1B1 inhibitors (e.g. cyclosporine) may increase the bioavailability of atorvastatin. The AUC of atorvastatin was significantly increased when atorvastatin 10 mg was co-administered with cyclosporine 5.2 mg/kg/day compared to atorvastatin alone. The concomitant use of atorvastatin and cyclosporine should be avoided.

Storage conditions

No special storage conditions are required.

Keep out of reach of children.

Shelf life - 3 years.